Published in Cancer Chemother Pharmacol on May 24, 2009
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res (2012) 1.65
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res (2011) 1.20
Administration of ON 01210.Na after exposure to ionizing radiation protects bone marrow cells by attenuating DNA damage response. Radiat Oncol (2012) 0.79
Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice. J Pharm Biomed Anal (2011) 0.75
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell (2005) 3.56
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol (2008) 1.84
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res (2012) 1.65
Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol (2002) 1.58
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A (2005) 1.30
Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents. J Med Chem (2007) 0.98
Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase. Bioorg Med Chem (2010) 0.97
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol (2013) 0.94
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clin Cancer Res (2012) 0.93
Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat Res (2009) 0.92
Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD(R) in mice. J Radiat Res (2012) 0.92
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res (2014) 0.88
Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood (2004) 0.85
Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1. Bioorg Med Chem (2005) 0.85
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer (2010) 0.85
A novel HPLC assay for pentamidine: comparative effects of creatinine and inulin on GFR estimation and pentamidine renal excretion in the isolated perfused rat kidney. J Pharm Pharm Sci (2002) 0.84
Aristolochic acid I metabolism in the isolated perfused rat kidney. Chem Res Toxicol (2011) 0.81
Renal excretion of emtricitabine I: effects of organic anion, organic cation, and nucleoside transport inhibitors on emtricitabine excretion. J Pharm Sci (2008) 0.80
Administration of ON 01210.Na after exposure to ionizing radiation protects bone marrow cells by attenuating DNA damage response. Radiat Oncol (2012) 0.79
Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. Eur J Pharm Sci (2010) 0.78
Radioprotective effects of ON 01210.Na upon oral administration. J Radiat Res (2012) 0.78
Characterization of pentamidine excretion in the isolated perfused rat kidney. J Antimicrob Chemother (2003) 0.78
Simulation of the pharmacokinetic profile of methazolamide in blood: effect of erythrocyte carbonic anhydrase binding on drug disposition. Pharm Res (2002) 0.77
Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib®), a phase III clinical stage anti-cancer agent. Org Biomol Chem (2013) 0.77
Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents. J Med Chem (2013) 0.77
(Z)-1-aryl-3-arylamino-2-propen-1-ones, highly active stimulators of tubulin polymerization: synthesis, structure-activity relationship (SAR), tubulin polymerization, and cell growth inhibition studies. J Med Chem (2012) 0.77
ON01210.Na (Ex-RAD®) mitigates radiation damage through activation of the AKT pathway. PLoS One (2013) 0.77
Effects of trimethoprim on the clearance of apricitabine, a deoxycytidine analog reverse transcriptase inhibitor, and Lamivudine in the isolated perfused rat kidney. J Pharmacol Exp Ther (2006) 0.77
Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species. Biopharm Drug Dispos (2011) 0.77
Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res (2013) 0.76
Differences in binding of (99m)Tc-disintegrins to integrin alphavbeta3 on tumor and vascular cells. Nucl Med Biol (2007) 0.75
Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure. J Pharm Pharmacol (2013) 0.75
Measuring drug concentrations using pulsatile microdialysis: theory and method development in vitro. Int J Pharm (2005) 0.75
Renal excretion of apricitabine in rats: ex vivo and in vivo studies. Eur J Drug Metab Pharmacokinet (2011) 0.75
Stability of sotalol hydrochloride in extemporaneously prepared oral suspension formulations. Int J Pharm Compd (2013) 0.75
Renal excretion of emtricitabine II. effect of trimethoprim on emtricitabine excretion: In vitro and in vivo studies. J Pharm Sci (2008) 0.75
Development and validation of a sensitive liquid chromatographic method for the analysis of a novel radioprotectant: ON 01210.Na. J Pharm Biomed Anal (2006) 0.75
Disposition of ON 01210.Na (Ex-RAD(R)), a novel radioprotectant, in the isolated perfused rat liver: probing metabolic inhibition to increase systemic exposure. J Pharm Sci (2012) 0.75
Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC/MS/MS. J Pharm Biomed Anal (2012) 0.75
Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney model. Drug Dev Ind Pharm (2010) 0.75
In vitro evaluation of the release of albuterol sulfate from polymer gels: effect of fatty acids on drug transport across biological membranes. Drug Dev Ind Pharm (2002) 0.75